Clinical trial
Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell…
NCT00325507 · Oxford BioMedica, Industry · Completed
Key facts
| NCT number | NCT00325507 |
|---|---|
| Title | Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma |
| Official title | Safety, Immunology, and Biological Activity Evaluation of TroVax® in Treatment of Patients With Locally Advanced or Metastatic Renal Carcinoma |
| Lead sponsor | Oxford BioMedica, Industry |
| Collaborators | The Methodist Hospital Research Institute ORION Clinical Services Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Biological, Drug |
| Interventions | TroVax, IL-2 |
| Enrollment | 25 |
| Start date | Nov 1, 2005 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | May 12, 2006 |
| Last update posted | Oct 19, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: